TP53 mutations at the time of diagnosis are found in 6%–21% of MDS patients and are more frequently associated with complex chromosomal abnormalities, and prior exposure to alkylating agents or radiation (therapy‐related MDS) [7, 8, 9]. The gene discussed is TP53; the disease is myelodysplastic syndrome.